ASH 2024: Circulating Tumor Cells Can Serve as Biomarker for Poor Outcomes in Multiple Myeloma

by | Dec 10, 2024 | Myeloma News | 0 comments

Source: Pharmacy Times articles

Luca Bertamini, MD highlights the potential clinical implications of using circulating tumor cells as a biomarker in patients with newly-diagnosed multiple myeloma.
Read More

Submit a Comment